MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom

The treatment options for patients with metastatic melanoma (MM) have been dramatically expanded in recent years with the approval of new drugs. The MEK (mitogen-acitvated protein kinase kinase) and BRAF (serine/threonine-protein kinase B-Raf coding gene) inhibitor combination therapy is currently p...

Descripción completa

Detalles Bibliográficos
Autores principales: Groselli, S., Heinrich, D., Lohmann, C. P., Maier, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2020
Materias:
Kasuistiken
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862533/
https://www.ncbi.nlm.nih.gov/pubmed/32248296
http://dx.doi.org/10.1007/s00347-020-01089-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862533/
https://www.ncbi.nlm.nih.gov/pubmed/32248296
http://dx.doi.org/10.1007/s00347-020-01089-3

Ejemplares similares